Akèy › Siròz
Etid klinik pou Siròz ap rekrite nan Etazini
36 etid pou Siròz ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA10 etid
- Cleveland, OH9 etid
- Dallas, TX8 etid
- Houston, TX7 etid
- Los Angeles, CA6 etid
- San Antonio, TX6 etid
- New York City, NY5 etid
- Miami, FL5 etid
- San Diego, CA4 etid
- Rochester, MN4 etid
- Durham, NC4 etid
- Chicago, IL4 etid
- Baltimore, MD4 etid
- Richmond, VA3 etid
- Philadelphia, PA3 etid
- Minneapolis, MN3 etid
- Indianapolis, IN3 etid
- Tampa, FL3 etid
- Nashville, TN3 etid
- Chandler, AZ3 etid
- Columbus, OH3 etid
Pa eta
- Arizona5 etid
- Colorado3 etid
- Florid7 etid
- Georgia3 etid
- Illinois4 etid
- Indiana4 etid
- Kalifòni8 etid
- Maryland4 etid
- Massachusetts10 etid
- Michigan3 etid
- Minnesota7 etid
- Missouri3 etid
- New York6 etid
- North Carolina6 etid
- Ohio12 etid
- Pennsylvania5 etid
- Tennessee5 etid
- Texas13 etid
- Virginia3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06632444A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07325526Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT05832229Molecular Mechanism of Exercise in Cirrhosis
Ap rekrite
Laj 21 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT05982769HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
Ap rekrite
Laj 21 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT05166499National Liver Cancer Screening Trial
Ap rekriteFaz 4
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06084234Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07610837Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 21, 2026 · NCT03208868Fibrosis Lessens After Metabolic Surgery
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06374875Measuring Patient Reported Needs in Outpatient Liver Disease Management
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT07191886Multi-analyte Blood Test Clinical Trial
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05199259Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05181826High Dose Albumin in Refractory Ascites
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT05867602Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT06138821Digoxin In NASH (CODIN)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou May 26, 2026 · NCT06588699Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou May 7, 2026 · NCT06950788COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT05692024Siemens Biomarker Multi-modality
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 3, 2026 · NCT07495332Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06525623Transitional Care Program for Fluid Overload in Cirrhosis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 9, 2026 · NCT06174272Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Feb 19, 2026 · NCT05526144Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 6, 2026 · NCT06526104A Study of SIPLIZUMAB in AILD and LT Patients
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT06455280The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT06871111Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Ap rekriteEtid obsèvasyon
Laj 18 a 80 · Tout sèks · Mizajou Oct 20, 2025 · NCT04613921Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.